MEI Pharma Inc Investor and Analyst Event - A New Chapter in PI3Kd Inhibition to Treat B-cell Malignancies Transcript
So thank you all for attending this morning. It's great to see you all. This is our Investor Analyst Day for MEI Pharma, in case you're not in the right room. Before we get started, we're very excited, I think we have a really interesting program I hope you all appreciate. And we'll be giving you an update on our lead programs. Just a few housekeeping -- just to keep the flow. It's a very long day, we know that you're all very busy. We'll try and keep everything on schedule.
If you do have any questions, we're going to try and hold them to the end, and there'll be a couple of microphones that will passed around. If for any reason you have a burning question and you can't stay till the end, just pass it to a friend next to you or give it to David Walsey, who I'm sure you all know, he's the one that badgers you all the time. And he can ask a question at the Q&A.
So there's the obligatory forward-looking statement slide. We will have forward-looking statements, and I invite you to go our SEC filings that can be found on
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |